<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680030</article-id><article-id pub-id-type="doi">10.3390/ijms252413530</article-id><article-id pub-id-type="publisher-id">ijms-25-13530</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Severity-Dependent Long-Term Post-Traumatic Changes in the Circulating Oxylipin Profile</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3864-6424</contrib-id><name><surname>Reinicke</surname><given-names>Madlen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-ijms-25-13530" ref-type="aff">1</xref><xref rid="fn1-ijms-25-13530" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Leyu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref><xref rid="fn1-ijms-25-13530" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Rang</surname><given-names>Moujie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Fuchs</surname><given-names>Carolin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Weikert</surname><given-names>Juliane</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-ijms-25-13530" ref-type="aff">1</xref><xref rid="af3-ijms-25-13530" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ke&#x000df;</surname><given-names>Annette</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0231-5116</contrib-id><name><surname>Kleber</surname><given-names>Christian</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Ceglarek</surname><given-names>Uta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-ijms-25-13530" ref-type="aff">1</xref><xref rid="af3-ijms-25-13530" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5051-0998</contrib-id><name><surname>Osterhoff</surname><given-names>Georg</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4670-4543</contrib-id><name><surname>Aust</surname><given-names>Gabriela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af2-ijms-25-13530" ref-type="aff">2</xref><xref rid="af4-ijms-25-13530" ref-type="aff">4</xref><xref rid="c1-ijms-25-13530" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ottria</surname><given-names>Roberta</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-25-13530"><label>1</label>Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, 04103 Leipzig, Germany; <email>madlen.reinicke@medizin.uni-leipzig.de</email> (M.R.); <email>juliane.weikert@medizin.uni-leipzig.de</email> (J.W.); <email>uta.ceglarek@medizin.uni-leipzig.de</email> (U.C.)</aff><aff id="af2-ijms-25-13530"><label>2</label>Research Laboratories and Clinic of Orthopedics, Trauma and Plastic Surgery, Leipzig University and University Hospital Leipzig, 04103 Leipzig, Germany; <email>leyu.zheng@medizin.uni-leipzig.de</email> (L.Z.); <email>moujie.rang@medizin.uni-leipzig.de</email> (M.R.); <email>carolin.fuchs@medizin.uni-leipzig.de</email> (C.F.); <email>annette.kess@medizin.uni-leipzig.de</email> (A.K.); <email>christian.kleber@medizin.uni-leipzig.de</email> (C.K.); <email>georg.osterhoff@medizin.uni-leipzig.de</email> (G.O.)</aff><aff id="af3-ijms-25-13530"><label>3</label>Leipzig Medical Biobank, Medical Faculty, Leipzig University, 04103 Leipzig, Germany</aff><aff id="af4-ijms-25-13530"><label>4</label>Research Laboratories and Clinic of Visceral, Transplantation, Vascular and Thoracic Surgery, Leipzig University and University Hospital Leipzig, 04103 Leipzig, Germany</aff><author-notes><corresp id="c1-ijms-25-13530"><label>*</label>Correspondence: <email>gabriela.aust@medizin.uni-leipzig.de</email>; Tel.: +49-341-97-17555; Fax: +49-341-97-17779</corresp><fn id="fn1-ijms-25-13530"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>17</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>25</volume><issue>24</issue><elocation-id>13530</elocation-id><history><date date-type="received"><day>04</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>14</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Trauma causes the breakdown of membrane phospholipids and the subsequent degradation of the released polyunsaturated fatty acids (PUFAs) to partially bioactive oxylipins. Here, we screened for circulating PUFAs and oxylipins in patients (n = 34) differing from those of uninjured controls (n = 25) and analyzed their diagnostic potential. Patients were followed up for 1 to 240 h after minor/moderate, severe, and very severe injuries. Of the targeted oxylipins, 13 out of 80 (13/80) were detected in almost all patients and controls. Injury caused a long-term decrease in 9- and 13-hydroxyoctadecadienoic acids and in several dihydroxyeicosatetraenoic acids, the stable derivatives of bioactive anti-inflammatory epoxyeicosatrienoic acids, compared to controls. Frequently, these oxylipins correlated inversely to injury severity, days in the intensive care unit and hospital, and/or procalcitonin and pro-inflammatory cytokine levels 48 up to 240 h after trauma. Notably, 20/80 oxylipins were detected in some patients but not or less often in controls. Many of these oxylipins increased transiently immediately after injury. Their level is partly correlated with adverse clinical parameters at this early time point. The circulating oxylipidome was markedly affected by trauma. Several oxylipins showed injury-dependent alterations at different time points in the post-traumatic course.</p></abstract><kwd-group><kwd>polyunsaturated fatty acid</kwd><kwd>oxylipin</kwd><kwd>arachidonic acid</kwd><kwd>injury</kwd><kwd>polytrauma</kwd></kwd-group><funding-group><award-group><funding-source>the German Research Foundation (DFG)</funding-source><award-id>209933838</award-id><award-id>390851560</award-id></award-group><award-group><funding-source>German Society for Clinical Chemistry and Laboratory Medicine e.V. (DGKL)</funding-source></award-group><award-group><funding-source>LIFE&#x02014;Leipzig Research Center for Civilization Diseases, Leipzig University</funding-source></award-group><award-group><funding-source>European Union by the European Regional Development Fund (ERDF)</funding-source></award-group><award-group><funding-source>the Open Access Publishing Fund of Leipzig University</funding-source></award-group><funding-statement>This research was funded by grants from the German Research Foundation (DFG) project number 209933838 to U.C. (Collaborative Research Center SFB-1052/A9) and project number 390851560 to J.W., the German Society for Clinical Chemistry and Laboratory Medicine e.V. (DGKL), and LIFE&#x02014;Leipzig Research Center for Civilization Diseases, Leipzig University. LIFE is funded by means of the European Union by the European Regional Development Fund (ERDF). Part of the Article Processing Charge was covered with the support of the Open Access Publishing Fund of Leipzig University.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-25-13530"><title>1. Introduction</title><p>Severe injury results in damage of macro- and micro-barriers, thereby exposing the immune system to damage-associated molecular patterns (DAMPs), which rapidly induce intracellular signaling in immune cells, particularly neutrophilic granulocytes, via pattern recognition receptors (PRR) [<xref rid="B1-ijms-25-13530" ref-type="bibr">1</xref>]. In consequence, activated immune cells release myriads of structurally and stereochemically distinct, partially bioactive oxylipins derived from polyunsaturated fatty acids (PUFAs) by oxygenation. PUFAs are vital components of cell membrane phospholipids in our body. Two, linoleic acid (LA; omega-6, &#x003c9;6) and alpha-linolenic acid (ALA, omega-3, &#x003c9;3), cannot be synthesized by humans and must be obtained from the diet. LA is metabolically converted to gamma-linolenic acid (GLA), dihomo-GLA (DHGLA), and finally to arachidonic acid (ARA) and ALA to eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), respectively.</p><p>PRR signaling causally activates (cytosolic) phospholipases A2 (PLA<sub>2</sub>), which then translocate to perinuclear and endoplasmic reticulum membranes [<xref rid="B2-ijms-25-13530" ref-type="bibr">2</xref>]. The PLA<sub>2</sub>s hydrolyze membrane phospholipids, resulting in the release of PUFAs that undergo further metabolism involving at least one step of dioxygen-dependent oxidation to form oxylipins. Their biosynthesis can either be enzymatic utilizing promiscuous cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P450 mixed-function oxidases (CYPs) or non-enzymatic via free radical mechanisms [<xref rid="B3-ijms-25-13530" ref-type="bibr">3</xref>].</p><p>ARA-derived eicosanoids produced by COX-1/-2 are predominantly pro-inflammatory and include classical prostaglandins (PGs) and thromboxanes (Txs). Leukotrienes (LTs) and lipoxins (LXs) are mainly generated by the activity of several LOXs. Bioactive but unstable epoxyeicosatrienoic acids (EETs) and their stable derivatives dihydroxyeicosatrienoic acids (DHETs) are converted by the most upstream members of the CYP family. Within the various originating oxylipin families, not all of which are listed here, there are members that exhibit either pro-inflammatory or anti-inflammatory/inflammation pro-resolving activities, some of which are context and cell-type dependent [<xref rid="B4-ijms-25-13530" ref-type="bibr">4</xref>,<xref rid="B5-ijms-25-13530" ref-type="bibr">5</xref>]. Very recently, oxylipins released after pyroptosis, a type of cell death, have been identified to help tissue healing. The supernatants of pyroptotic bone-marrow-derived macrophages and CD14<sup>+</sup> blood monocytes induced a sharp increase in the rate of fibroblast wound closure [<xref rid="B6-ijms-25-13530" ref-type="bibr">6</xref>]. Surprisingly, the de novo-generated oxylipin PGE<sub>2</sub> was identified as promoting this healing effect.</p><p>Despite the important role of circulating, partly bioactive oxylipins they have not been investigated long-term in injured patients. Overall, oxylipodomic profiling from fluids and tissues is challenging due to the low abundance, instability, and difficult separation of structurally similar metabolites [<xref rid="B7-ijms-25-13530" ref-type="bibr">7</xref>]. Here, we applied targeted liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based profiling of seven circulating PUFAs and 80 PUFA-derived metabolites [<xref rid="B7-ijms-25-13530" ref-type="bibr">7</xref>,<xref rid="B8-ijms-25-13530" ref-type="bibr">8</xref>,<xref rid="B9-ijms-25-13530" ref-type="bibr">9</xref>]. Plasma was collected at 1, 8, 24, 48, 120, and 240 h post-injury to observe the immediate effects of trauma and to track long-term anti-inflammatory/pro-resolving mediators. We included trauma patients with a wide range of injury severity to observe the effects of minor/moderate to very severe trauma, compared with an uninjured control group, from which we obtained plasma once. Our aim was to determine whether oxylipins could serve as potential markers for monitoring the time course and outcome of injured patients.</p></sec><sec sec-type="results" id="sec2-ijms-25-13530"><title>2. Results</title><sec id="sec2dot1-ijms-25-13530"><title>2.1. Patient Groups Differ in Their Clinico-Pathological and Laboratory Parameters</title><p>Patients were assigned to three categories according to their injury severity score (ISS): minor/moderately (ISS &#x0003c; 16, n = 11, group 1), severely (ISS 16&#x02013;24, n = 11, group 2), and very severely injured (ISS &#x02265; 25, n = 14, group 3) [<xref rid="B10-ijms-25-13530" ref-type="bibr">10</xref>]. The length of stay at the intensive care unit (ICU) and in the hospital, as well as the Sequential Organ Failure Assessment (SOFA) score at 24 h after trauma, differed between the minor/moderately and very severely injured patients (<xref rid="ijms-25-13530-t001" ref-type="table">Table 1</xref>). The majority of the very severely injured patients suffered from thoracic and abdominal injuries, as well as spinal injuries (<xref rid="app1-ijms-25-13530" ref-type="app">Table S1</xref>).</p><p>Heat maps visualize the relationship between the patient&#x02019;s parameters and scores at 1 and 24 h after injury (<xref rid="app1-ijms-25-13530" ref-type="app">Figure S1A,B</xref>). Overall, the expected correlations between ISS, days at ICU and in the hospital, the various trauma-related clinical scores such as the SOFA score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Simplified Acute Physiology Score 3 (SAPS3), and the Glasgow Coma Scale (GCS), as well as procalcitonin (PCT) and pro-inflammatory cytokine levels were present in the traumatized patients. Compared to minor/moderate injury, very severe injury was associated with higher IL-6 and IL-8 levels, a sign of inflammation, up to 48 h after trauma (<xref rid="app1-ijms-25-13530" ref-type="app">Figure S1C</xref>), which is consistent with previously published data [<xref rid="B11-ijms-25-13530" ref-type="bibr">11</xref>].</p></sec><sec id="sec2dot2-ijms-25-13530"><title>2.2. Long-Term Deficiency of &#x003c9;-3 PUFAs in Traumatized Patients Compared to Controls</title><p>Seven PUFAs were quantified in all patients and controls (<xref rid="ijms-25-13530-f001" ref-type="fig">Figure 1</xref>): &#x003c9;-6 PUFAs LA, GLA, DHGLA, and ARA, and &#x003c9;-3 PUFAs ALA, EPA, and DHA, with GLA and ALA being detected as sum parameter. There was an obvious heterogeneity in the absolute PUFA levels between the controls but also between the patients immediately after injury, likely reflecting the different (pre-injury) nutritional status. Such a variability was also observed for several PUFAs before surgical intervention [<xref rid="B12-ijms-25-13530" ref-type="bibr">12</xref>].</p><p>Immediately, 1&#x02013;8 h after injury levels of &#x003c9;-6 PUFAs LA and ARA, and also of sum GLA/ALA were higher in traumatized patients compared to controls (<xref rid="ijms-25-13530-f001" ref-type="fig">Figure 1</xref>A). In the further posttraumatic course levels of each PUFA decreased until 120&#x02013;240 h in the majority of patients. Patients showed an obvious long-term decrease for &#x003c9;-3 PUFAs EPA and DHA 24&#x02013;240 h after injury. There were no significant differences in any PUFA between the patient groups (<xref rid="ijms-25-13530-f001" ref-type="fig">Figure 1</xref>B).</p><p>Because &#x003c9;-3 PUFA levels were inversely correlated with mortality risk [<xref rid="B13-ijms-25-13530" ref-type="bibr">13</xref>], we also calculated the ratio of &#x003c9;-6 LA and ARA to &#x003c9;-3 EPA and DHA levels (<xref rid="ijms-25-13530-f001" ref-type="fig">Figure 1</xref>C). These ratios increased in the post-traumatic course, best seen for ARA/DHA. The ratios were not different between the patient groups and also similar between the various time points 1&#x02013;240 h after injury.</p></sec><sec id="sec2dot3-ijms-25-13530"><title>2.3. Many Oxylipins, Present Transiently Immediately After Injury in Some Patients, Were Much Less Detectable or Not Detected at All in Controls</title><p><xref rid="app1-ijms-25-13530" ref-type="app">Figure S2</xref> provides a simplified scheme of the oxylipins derived from &#x003c9;-6 PUFAs that are theoretically accessible in our targeted analyses. Of the 80 targeted oxylipins 11b-PGE2 and 15-keto-PGF2a as well as 8(S)-HETE and 12(S)-HETE are detected as sum parameters. <xref rid="ijms-25-13530-f002" ref-type="fig">Figure 2</xref> visualizes the oxylipins effectively detected. The main pathways involved and the relationships between PUFAs and metabolites are indicated but not all could be considered.</p><p>Around 60% of the targeted circulating oxylipins were under the detection limit in any patient and control (<xref rid="app1-ijms-25-13530" ref-type="app">Table S2</xref>). A total of 13 out of 80 (13/80) of the targeted metabolites were found in almost all patients at each time point and in almost all controls. For comparisons of the oxylipin levels between controls and all patients and between patient groups, only metabolites with at least 90% detectable values of the patients in each group were considered, undetectable values were imputed. The data of these oxylipins are shown as boxplots in our study.</p><p>20/80 of the targeted metabolites were detected in less than 90% of the patients at any time point. These oxylipins were less often (6/20) or even not detected (14/20) in controls (<xref rid="ijms-25-13530-t002" ref-type="table">Table 2</xref>). For each of these oxylipins, we calculated the frequency of patients showing detectable values in the posttraumatic course and visualized these data (<xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref>). Obviously, the frequencies were, in most cases, highest immediately after injury, afterwards they declined. Thus, 1 h after injury for many of these oxylipins the frequency of patients with detectable oxylipins values was significantly higher compared to that of the controls. <xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref> shows the data also for each patient group. However, the number of patients was too low for statistical group comparisons.</p><p>Original data of the patients and controls are provided in <xref rid="app1-ijms-25-13530" ref-type="app">Table S3</xref>.</p></sec><sec id="sec2dot4-ijms-25-13530"><title>2.4. Late Decrease of LA-Derived 9- and 13-HODE After Very Severe Injury</title><p>In the following, we discuss the metabolites one by one depending on the PUFA from which they derive and on the main pathway in which they emerge.</p><p>Two stable monohydroxy oxidation products derived from LA, 9-hydroxyoctadecadienoic acid (HODE) and 13-HODE, were targeted. Both were quantifiable in all patients at each time point and in all controls. Compared with controls, traumatized patients showed an obvious decrease for both metabolites in the posttraumatic course from 8 h onward. Notably, 13-HODE was lower 48 h up to 240 h after trauma in patients who had sustained very severe compared to those with minor/moderate injury (<xref rid="ijms-25-13530-f004" ref-type="fig">Figure 4</xref>A).</p></sec><sec id="sec2dot5-ijms-25-13530"><title>2.5. Several Oxylipins of the COX-Generated Prostaglandin and Thromboxane Families Appeared Immediately After Injury</title><p>ARA-derived oxylipins generated in the COX pathway, which include many prostaglandins and thromboxanes, were detected in some, but not all patients and often not in controls (<xref rid="ijms-25-13530-f002" ref-type="fig">Figure 2</xref> and <xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref>). 6-keto-PGF<sub>1&#x003b1;</sub>, PGE<sub>2</sub>, 13,14-dihydro-15-keto-PGE2, PGF<sub>2&#x003b1;</sub>, and 13,14-dihydro-15-keto-PGF<sub>2&#x003b1;</sub> were significantly more often detected in patients 1 h after injury compared to the controls (<xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref>). When examining the patient groups, in tendency 11-dehydro-TxB<sub>2</sub>, 11b-PGE2/15-keto-PGF<sub>2&#x003b1;</sub>, 13,14-dihydro-15-keto-PGE<sub>2</sub>, and 13,14-dihydro-15-keto-PGF<sub>2&#x003b1;</sub> were detected more often in very severe compared to less injured patients 1&#x02013;8 h post-traumatically (<xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec2dot6-ijms-25-13530"><title>2.6. Early Increase in LOX-Generated ARA-Derived Oxylipins After Injury</title><p>ARA, metabolized by 5-LOX, leads to the generation of inflammatory leukotrienes including leukotriene E<sub>4</sub> (LTE<sub>4</sub>) which was rarely detected in patients but not at all in controls (<xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref>). In this pathway, 5(S)-hydroxyeicosatetraenoic acid (HETE) was quantifiable in all patients. This was also the case for 8(S)-/12(S)-, and 15(S)-HETE, that originate from 8-, 12-, and 15-LOX activity, and for tetranor-12(S)-HETE, that derived non-enzymatically from 12(S)-HETE. These oxylipins increased immediately 1&#x02013;8 h after injury in patients compared to controls. The patient groups did not differ with respect to these metabolites (<xref rid="app1-ijms-25-13530" ref-type="app">Figure S3</xref>).</p></sec><sec id="sec2dot7-ijms-25-13530"><title>2.7. Oxylipins Generated by CYP Activity: Lower Levels of Several DHETs After Very Severe Injury</title><p>The CYP system, which utilizes ARA as a substrate, comprises two main branches of enzymes: epoxygenases and &#x003c9;-hydroxylases. Members of the CYP2C and CYP2J families of CYP epoxygenases metabolize ARA to four biologically active epoxyeicosatrienoic acids (EETs): 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET. EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to more stable but less biologically active DHETs, differing in the position of the two hydroxy groups at the 20 carbon backbone (<xref rid="ijms-25-13530-t002" ref-type="table">Table 2</xref>). Thus, evaluating plasma DHETs reflects the EET levels in an indirect way. 1/4 EETs, 14,15-EET, was detectable in 5/11 minor/moderately injured patients and only in 1/14 very severely injured patients 1 h after injury. The resulting four DHETs, detectable in all patients and controls, were lower in very severely compared with the minor/moderately and partly with the severely injured patients. This was not only seen immediately, 1 and partly also 8 h, but also later, 48&#x02013;120 h after injury (<xref rid="ijms-25-13530-f004" ref-type="fig">Figure 4</xref>B). Compared to controls, traumatized patients showed an obvious decrease for 11,12-DHET and 14,15-DHET 24&#x02013;240 h after injury.</p><p>The CYP4A and CYP4F &#x003c9;-hydroxylase subfamilies convert ARA to 16(S)-, 17(S)-, 18-, 19(S)-, and 20-HETE (<xref rid="ijms-25-13530-f002" ref-type="fig">Figure 2</xref>), which were detected either in all (16(S)-HETE, <xref rid="app1-ijms-25-13530" ref-type="app">Figure S3</xref>) or in some patients, respectively. In the control group 17(S)-HETE and 20-HETE were not detected, and 19(S)-HETE was less frequently present compared to all patients (<xref rid="ijms-25-13530-f003" ref-type="fig">Figure 3</xref>, <xref rid="ijms-25-13530-t002" ref-type="table">Table 2</xref>). 18-HETE was the only metabolite detected in all controls but in less than 80% of the patients.</p></sec><sec id="sec2dot8-ijms-25-13530"><title>2.8. 11(S)-HETE Increased Immediately After Injury</title><p>11(S)-HETE, generated by lipid peroxidation from ARA, was detected in all patients and controls. It transiently increased immediately after injury compared to controls and decreased continuously in the further course. Very severely injured patients showed lower 11(S)-HETE levels compared to less injured patients 48&#x02013;120 h after injury (<xref rid="app1-ijms-25-13530" ref-type="app">Figure S3</xref>).</p></sec><sec id="sec2dot9-ijms-25-13530"><title>2.9. Several Oxylipins Correlate to Clinical Parameters in the Posttraumatic Course</title><p>Finally, we related the PUFA and oxylipin data with the clinical parameters available at each time point and visualized the significant results in a heatmap (<xref rid="ijms-25-13530-f005" ref-type="fig">Figure 5</xref>). As expected, PUFA levels were not informative, but the levels of several oxylipins were.</p><p>Two metabolite groups, detected in almost all patients, showed inverse relationships with injury severity, prolonged ICU and/or hospital stay, as well as PCT and/or pro-inflammatory cytokine levels, especially late in the post-traumatic course. These were LA-derived 9- and 13-HODE, which are likely to be of interest as potential biomarkers at 48 h but also up to 240 h after trauma. The second metabolite group is the various ARA-derived DHETs showing an inverse relation to the ISS and partly to other adverse clinical parameters at 1, 48, and 120 h after trauma.</p><p>Furthermore, several oxylipins arising or increasing transiently immediately after injury are directly related to adverse clinical parameters early in the post-traumatic time course; later time points could often not be examined because of the low number of patients with detectable values. Among these are ARA-derived 11-dehydroxy-TxB<sub>2</sub> and tetranor-12(S)-HETE correlating to the ISS, length of stay at the ICU and/or in the hospital, and pro-inflammatory cytokine levels 1 and/or 8 h after injury.</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-25-13530"><title>3. Discussion</title><p>In the present study, we targeted postinjury 80 circulating oxylipins that partly exhibit context- and cell-type-specific pro- or anti-inflammatory properties. 16% were detected in almost all patients, while 25% could be quantified in some. Mostly, the more stable but often biologically inactive intermediates could be quantified, confirming previous studies [<xref rid="B14-ijms-25-13530" ref-type="bibr">14</xref>].</p><p>A number of the oxylipins detected in almost all patients and controls are potential markers for the time course and outcome of traumatized patients. This concerns the first 9- and 13-HODE; their levels correlate inversely to days at ICU, ISS, and IL-6 levels late, until ten days after injury. Thus, both may predict adverse outcomes after trauma. HODEs are generated by LOXs or non-enzymatically, and their pro- or anti-inflammatory biological effects are context-specific [<xref rid="B15-ijms-25-13530" ref-type="bibr">15</xref>]. Exemplarily, in early atherosclerosis, 13-HODE is generated in macrophages enzymatically by 15-LOX-1. This probably activates protective mechanisms that increase the clearance of lipid and cellular debris from the vessel wall. In later atherosclerosis, non-enzymatic oxidation of LA generates both 9- and 13-HODE. At this stage of the disease, and with the pro-inflammatory actions of 9-HODE after binding to GPR132, the effects of HODEs may be predominantly harmful.</p><p>Secondly, DHETs, the stable inactive derivatives of the bioactive EET regioisomers may be such markers. Patients with the most severe injuries exhibited the lowest levels of the resulting DHETs up to 120 h after injury. Traumatized patients were deficient in 11,12- and 13,14-DHET late after injury when compared with controls. EETs, identified as autocrine and paracrine signaling lipid mediators, regulate diverse biological processes (reviewed in [<xref rid="B16-ijms-25-13530" ref-type="bibr">16</xref>]). Notably, they mediate a number of anti-inflammatory effects [<xref rid="B16-ijms-25-13530" ref-type="bibr">16</xref>,<xref rid="B17-ijms-25-13530" ref-type="bibr">17</xref>,<xref rid="B18-ijms-25-13530" ref-type="bibr">18</xref>,<xref rid="B19-ijms-25-13530" ref-type="bibr">19</xref>]. Exemplarily, 11,12 EET rescued deteriorated wound healing in a combined model of hyperglycemia and ischemia by resolution of inflammation and augmentation of neovascularization [<xref rid="B20-ijms-25-13530" ref-type="bibr">20</xref>]. Because EETs are highly unstable and rapidly converted by sEHs to DHET, approaches to increase EET levels were conducted [<xref rid="B16-ijms-25-13530" ref-type="bibr">16</xref>,<xref rid="B18-ijms-25-13530" ref-type="bibr">18</xref>,<xref rid="B19-ijms-25-13530" ref-type="bibr">19</xref>,<xref rid="B20-ijms-25-13530" ref-type="bibr">20</xref>,<xref rid="B21-ijms-25-13530" ref-type="bibr">21</xref>,<xref rid="B22-ijms-25-13530" ref-type="bibr">22</xref>,<xref rid="B23-ijms-25-13530" ref-type="bibr">23</xref>]. Experimentally, the potentiation of EET activity can be achieved in various ways in mice, including loss of sEH or endothelial-specific overexpression of human <italic toggle="yes">CYPJ2</italic> or <italic toggle="yes">CYP2C8</italic>. This inhibited inflammatory gene expression and signaling pathways in endothelial cells and monocytes, as well as in models of cardiovascular diseases. The sEH inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU) dampened inflammation and the generation of DHET in a burned mouse model [<xref rid="B21-ijms-25-13530" ref-type="bibr">21</xref>]. In human studies, the application of stable inhibitors of sEH has been employed to enhance the availability of circulating EETs in patients [<xref rid="B23-ijms-25-13530" ref-type="bibr">23</xref>].</p><p>Several metabolites immediately present after injury in a part of the traumatized patients were not detected in any control. These frequently injury-dependent occurring oxylipins belong to ARA-derived metabolites mainly generated by COX-, partly also by LOX-activity, with primarily pro-inflammatory properties such as PGE<sub>2</sub> and its derivative 13,14-dihydro-15-keto-PGE<sub>2</sub>. Immediately after trauma oxylipins with pro-inflammatory properties tended to be more often detectable in patients with an ISS &#x02265; 25 compared to patients with a lower ISS. 13,14-dihydroxy-15keto-PGE<sub>2</sub>, 13,14-dihydroxy-15keto-PGF<sub>2&#x003b1;</sub> and 11&#x003b2;-PGE2/15-keto-PGF<sub>2&#x003b1;</sub> are widely considered as stable, inactive forms of PGE<sub>2</sub> or PGF<sub>2&#x003b1;</sub>, but recent data show that 15-keto-PGE<sub>2</sub> is bioactive and could terminate PGE<sub>2</sub>&#x02013;evoked signaling [<xref rid="B24-ijms-25-13530" ref-type="bibr">24</xref>,<xref rid="B25-ijms-25-13530" ref-type="bibr">25</xref>]. Furthermore,11-dehydro-TxB<sub>2</sub> was more frequently detected immediately after severe and very severe injury. It is produced from the breakdown of TxB<sub>2</sub>, a stable, inactive degradation product of TxA<sub>2</sub>. TxA<sub>2</sub> is synthesized by platelets in response to native or exogenous added stimuli. In the past, PGF<sub>2&#x003b1;</sub>, PGE<sub>2</sub>, and/or TxB<sub>2</sub> have already been associated with trauma, either in experimental models or patients. In rat spinal cord injury models, TxB<sub>2</sub> increased in the spinal cord [<xref rid="B26-ijms-25-13530" ref-type="bibr">26</xref>], and PGE<sub>2</sub> and TxB<sub>2</sub> were elevated in cerebrospinal fluid [<xref rid="B27-ijms-25-13530" ref-type="bibr">27</xref>]. In humans, TxB<sub>2</sub> was found to be elevated at admission to the hospital after traumatic brain injury [<xref rid="B28-ijms-25-13530" ref-type="bibr">28</xref>] and in patients with recent major trauma or active sepsis [<xref rid="B29-ijms-25-13530" ref-type="bibr">29</xref>].</p><p>Notably, around 60% of the targeted circulating metabolites were under the detection limit in any patient and control in our study. This concerns many unstable intermediates of COX- or non-enzymatically generated prostaglandins or of LOX-generated leukotrienes and lipoxins. Nearly all of these oxylipins were also not detected, if targeted, in other studies quantifying oxylipins in human plasma [<xref rid="B30-ijms-25-13530" ref-type="bibr">30</xref>].</p><p>Initially, studies investigating oxylipins after trauma focused on brain injury because the brain is particularly rich in long-chain PUFAs, especially in excitable membranes [<xref rid="B31-ijms-25-13530" ref-type="bibr">31</xref>]. Experimental models permit the direct quantification of oxylipin release in the brain [<xref rid="B32-ijms-25-13530" ref-type="bibr">32</xref>,<xref rid="B33-ijms-25-13530" ref-type="bibr">33</xref>]. In a pediatric rat model, within the first hour following trauma, brain oxylipins surge with numerous eicosanoids and octadecanoids [<xref rid="B32-ijms-25-13530" ref-type="bibr">32</xref>]. Afterward, their levels decrease, although some remain elevated. A similar posttraumatic time course was seen for many circulating oxylipins in our study. Furthermore, the use of 3D MALDI-MSI to visualize lipid distribution in sectioned injured rat brains demonstrated lipid changes associated with traumatic brain injury and identified lesion-specific lipids [<xref rid="B33-ijms-25-13530" ref-type="bibr">33</xref>]. In humans, after traumatic brain injury, the levels of ARA, DHA, 5-HETE, and 12-HETE, the only PUFAs/oxylipins targeted in the cited study, were 10-fold higher in the cerebral spinal fluids of patients compared to controls [<xref rid="B34-ijms-25-13530" ref-type="bibr">34</xref>].</p><p>Profiling circulating oxylipids is challenging. To address the low abundance and instability of released oxylipins in blood, Orr et al. [<xref rid="B35-ijms-25-13530" ref-type="bibr">35</xref>] evaluated the transcriptome of circulating leukocytes in trauma patients. The expression of 18 genes critical to the synthesis, signaling, and metabolism of pro-inflammatory oxylipins and SPMs was quantified in 96 patients after blunt trauma with uncomplicated and complicated recoveries. Patients with complicated courses and worse clinical outcomes exhibited higher expression ratios of leukotriene to resolvin pathway genes. However, transcriptomic profiling cannot reflect the high diversity of released oxylipids as detected in our patients.</p><p>In summary, the PUFA-derived oxylipidome of injured patients differs obviously from that of uninjured controls. The posttraumatic course is characterized by an early enhanced release of pro-inflammatory ARA-derived, COX-and LOX-generated oxylipins, followed by a subsequent decrease in 9- and 13-HODE, as well as in 11,12- and 13,14-DHET. The levels of several oxylipins correlate to clinical parameters.</p><sec><title>Limitation of the Study</title><p>Our study focused on &#x003c9;-6 derived metabolites. &#x003c9;-3 EPA and DHA can be metabolized to LXA<sub>5</sub> and E-resolvins and D-resolvins, protectins, and maresins, respectively [<xref rid="B36-ijms-25-13530" ref-type="bibr">36</xref>,<xref rid="B37-ijms-25-13530" ref-type="bibr">37</xref>]. These oxylipins, not having been targeted here, are characterized as specialized pro-resolving mediators (SPMs), terminating inflammation by exerting anti-inflammatory and pro-resolving activities (reviewed in [<xref rid="B37-ijms-25-13530" ref-type="bibr">37</xref>]). However, numerous studies show that SPMs are only found at extremely low levels or are even undetectable in biological samples [<xref rid="B38-ijms-25-13530" ref-type="bibr">38</xref>,<xref rid="B39-ijms-25-13530" ref-type="bibr">39</xref>,<xref rid="B40-ijms-25-13530" ref-type="bibr">40</xref>].</p><p>The levels of certain oxylipins are related to age [<xref rid="B41-ijms-25-13530" ref-type="bibr">41</xref>,<xref rid="B42-ijms-25-13530" ref-type="bibr">42</xref>], a fact not considered in our study. Three major 12-LOX products were present at high levels in young females (20&#x02013;55 years) compared with older females and males (55+) [<xref rid="B42-ijms-25-13530" ref-type="bibr">42</xref>]. The median age of our patients and controls was ~58 years.</p><p>Overall, the sample sizes are quite small, limiting statistical power. The number of patients, especially those with very severe injuries, was too low to verify the suitability of several detected oxylipins as potential markers for the posttraumatic course and outcome. It would be beneficial to include additional clinical parameters, such as the timely-matched white blood cell count and daily clinical SOFA, APACHE II, and SAPS3 scores over the whole post-traumatic course. This would allow a more detailed evaluation of circulating oxylipins in relation to the clinical context.</p></sec></sec><sec id="sec4-ijms-25-13530"><title>4. Materials and Methods</title><sec id="sec4dot1-ijms-25-13530"><title>4.1. Clinical Study on Traumatized Patients and Controls</title><p>We included 36 injured patients in our study (<xref rid="ijms-25-13530-t001" ref-type="table">Table 1</xref> and <xref rid="app1-ijms-25-13530" ref-type="app">Table S1</xref>). Exclusion criteria were age &#x0003c; 18 years, life expectancy &#x0003c; 24 h, participation in other studies, cardiopulmonary reanimation on the accident scene or death immediately after hospital admission, known or suspected pregnancy, and radiotherapy or chemotherapy within the previous 3 months. The ISS was estimated after whole-body computed tomography and verified retrospectively. By definition, an ISS of 1&#x02013;8 is considered minor, 9&#x02013;15 moderate, 16&#x02013;24 severe, and &#x02265;25 very severe [<xref rid="B10-ijms-25-13530" ref-type="bibr">10</xref>]. The SOFA score, the APACHE II score, SAPS3, and GCS were calculated at 1, 8, and 24 h. In patients with an ISS &#x0003c; 16, daily scores could not be applied after 24 h because the necessary score parameters were not gathered.</p><p>We included a control group (n = 25) of an age- (median 60.5 (50.3&#x02013;69.3) years) and sex-matched (9 females) cohort from the LIFE-Leipzig-Heart study [<xref rid="B43-ijms-25-13530" ref-type="bibr">43</xref>,<xref rid="B44-ijms-25-13530" ref-type="bibr">44</xref>]. The blood donors of this control group had normal values in all basic clinical parameters such as pro-inflammatory markers, fat metabolic parameters, enzyme levels, or white blood cell count, and showed angiographically unsuspicious coronary arteries.</p></sec><sec id="sec4dot2-ijms-25-13530"><title>4.2. Blood Sample Preparation</title><p>Blood was collected from the injured patients 1, 8, 24, 48, 120, and 240 h after hospital admission. Tolerance for blood taking was &#x000b1;10% per time point. The control group had an immediate blood taking. To obtain EDTA plasma or serum, the respective monovette (Sarstedt AG, N&#x000fc;mbrecht, Germany) was centrifuged at 2000&#x000d7; <italic toggle="yes">g</italic> for 10 min at 20 &#x000b0;C. The supernatants were transferred to coded cryotubes, stored at &#x02212;80 &#x000b0;C, and thawed only once because many metabolites are sensitive to inaccurate processing of blood samples. Influencing factors such as pre-centrifugation delay &#x0003e; 2 h, long-term storage above &#x02212;80 &#x000b0;C, or repeated freeze&#x02013;thaw cycles may lead to a significant increase in metabolites [<xref rid="B7-ijms-25-13530" ref-type="bibr">7</xref>,<xref rid="B9-ijms-25-13530" ref-type="bibr">9</xref>].</p></sec><sec id="sec4dot3-ijms-25-13530"><title>4.3. LC-MS/MS of PUFAs and Oxylipins</title><p>Targeted LC-MS/MS analysis for quantification of 7 PUFAs and 80 oxylipins was performed according to our previously published method with modifications [<xref rid="B7-ijms-25-13530" ref-type="bibr">7</xref>,<xref rid="B8-ijms-25-13530" ref-type="bibr">8</xref>]. Separate LC-MS/MS methods for PUFAs and for oxylipins were applied. The oxylipin method was transferred to a more sensitive mass spectrometer. Chromatographic separation was optimized for each method.</p><p>Both methods could be conducted after the same sample preparation. In brief, 100 &#x000b5;L plasma was mixed with 225 &#x000b5;L precipitation solution containing the internal standards (50 ng/mL for PUFAs and 5 ng/mL for oxylipins). After vortexing for 2 min, samples were centrifuged for 5 min at 10,000&#x000d7; <italic toggle="yes">g</italic>, and the clear supernatant was transferred into independent aliquots for each method. Separate seven-point calibration was performed in the concentration range of 100&#x02013;10,000 ng/mL for PUFAs and 100&#x02013;10,000 pg/mL for each oxylipin.</p><p>The LC system from Shimadzu (Duisburg, Germany) was similar for both methods and consisted of a Prominence UFLC system with two high-pressure gradient pumps (LC-20ADXR), an isocratic pump (LC-20AD), a column oven (CTO-20AC), a controlling module (CBM-20A), and a HTS PAL autosampler from CTC Analytics (Zwingen, Switzerland).</p><p>An on-line SPE was implemented in both methods using a Strata-X extraction column (20 &#x000d7; 2 mm i.d., 25 &#x000b5;m particle size; Phenomenex, Aschaffenburg, Germany) and MeOH/water/FA 10:90:0.02 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, with a flow rate of 3 mL/min for 1 min. Chromatographic separation for both methods was performed on a core-shell LC column (Kinetex C<sub>18</sub>, 100 &#x000d7; 2.1 mm i.d., 2.6 &#x000b5;m particle size; Phenomenex).</p><p>For PUFAs, the flow rate was set to 0.5 mL/min and the gradient was applied as follows: 0 to 100% eluent B in 8.8 min (eluent A: water/ACN/FA 63:37:0.02 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, eluent B: iPrOH/ACN 50:50 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>), 100% B for 1.2 min, re-equilibration of the columns for 2 min. The column oven was kept at 35 &#x000b0;C. Injection volume was 10 &#x000b5;L. The LC system was coupled to a QTRAP<sup>&#x000ae;</sup> 5500 mass spectrometer (SCIEX, Framingham, MA, USA) equipped with a Turbo V&#x02122; ion spray source operating in negative ion mode.</p><p>For oxylipins, the flow rate was set to 0.7 mL/min and the gradient was applied as follows: 15 to 100% eluent B in 13.1 min (eluent A: water/MeOH 90:10 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>, eluent B: MeOH/water 90:10 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>), 100% B for 2 min, re-equilibration of the columns for 2 min. The column oven was kept at 50 &#x000b0;C. Injection volume was 10 &#x000b5;L. The LC system was coupled to a QTRAP<sup>&#x000ae;</sup> 6500+ mass spectrometer (SCIEX) equipped with a Turbo V&#x02122; ion spray source operating in negative ion mode.</p><p><xref rid="ijms-25-13530-t002" ref-type="table">Table 2</xref> and <xref rid="app1-ijms-25-13530" ref-type="app">Table S2</xref> give an overview and useful information on the targeted PUFAs and oxylipins.</p></sec><sec id="sec4dot4-ijms-25-13530"><title>4.4. Quantitation of Further Parameters</title><p>IL-6, IL-8, and MCP-1 (CCL2) were quantified in serum using the human IL-6, IL-8, and MCP-1 BD OptEIA ELISA kits (BD Life Sciences, Heidelberg, Germany). Procalcitonin (PCT) was quantified in plasma using the TRACE technology (Roche Pharma AG, Grenzach-Wyhlen, Germany).</p></sec><sec id="sec4dot5-ijms-25-13530"><title>4.5. Statistical Analyses</title><p>The absolute levels of PUFAs and metabolites were provided. For metabolites not present in a measured sample, values below the limit of detection were imputed with half the minimal measured value [<xref rid="B45-ijms-25-13530" ref-type="bibr">45</xref>]. This imputation was conducted only for metabolites with at least 10% values less than the limit of detection at the indicated time point. If no patient sample was available at a certain time point because the patient underwent surgery or already left the hospital, this sample was treated as missing. For continuous variables median and the interquartile range [25th&#x02013;75th percentile] were used. Data were analyzed using SPSSv27 (IBM, Armonk, NY, USA) and GraphPad Prism10.2 (GraphPad Software, Boston, MA, USA). Box plots are shown as mean/25&#x02013;75% percentiles with 10&#x02013;90 percentile whiskers. <italic toggle="yes">p</italic> values were two-sided and &#x003b1; &#x0003c; 0.05 was used for hypothesis testing. We corrected for multiple comparisons by controlling the False Discovery Rate using the Two-stage step-up method of Benjamini, Krieger, and Yekutieli.</p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-25-13530"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ijms252413530/s1">https://www.mdpi.com/article/10.3390/ijms252413530/s1</uri>.</p><supplementary-material id="ijms-25-13530-s001" position="float" content-type="local-data"><media xlink:href="ijms-25-13530-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization U.C. and G.A.; methodology M.R. (Madlen Reinicke), U.C. and J.W.; recruitment of patients and patient&#x02019;s data L.Z., M.R. (Moujie Rang), C.F., A.K., C.K. and G.O.; resources G.A. and G.O.; sample preparation and measurements: M.R. (Madlen Reinicke), M.R. (Moujie Rang) and J.W.; data analysis G.A., M.R. (Madlen Reinicke), L.Z. and J.W.; writing and original draft preparation G.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The protocol of the prospective study investigating patients with trauma was approved by the Ethics committee of Leipzig University (Reg. No. 188-17). Samples and data were collected after written informed consent was obtained from patients or their legal guardians. The LIFE-Leipzig-Heart study [<xref rid="B43-ijms-25-13530" ref-type="bibr">43</xref>,<xref rid="B44-ijms-25-13530" ref-type="bibr">44</xref>] was approved by the Ethics Committee of Leipzig University (Reg. No. 276-2005) and is registered at ClinicalTrials.gov (NCT00497887).</p></notes><notes><title>Informed Consent Statement</title><p>All participants provided written informed consent. The research involving human participants has been performed in accordance with the Declaration of Helsinki.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The general patient data and quantitative data of the analyzed clinical and LC-MS/MS parameters are provided in the <xref rid="app1-ijms-25-13530" ref-type="app">Supplementary Materials</xref>, <xref rid="app1-ijms-25-13530" ref-type="app">Table S3</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>Acute Physiology And Chronic Health Evaluation (APACHE), base excess concentration of extracellular fluid (BE), Glasgow Coma Scale (GCS), injury severity score (ISS), intensive care unit (ICU), pattern-recognition receptor (PRR), phospholipase A (PLA), polyunsaturated fatty acids (PUFA), procalcitonin (PCT), soluble epoxide hydrolase (sEH), Simplified Acute Physiology Score 3 (SAPS3), Sequential Organ Failure Assessment (SOFA), and specialized pro-resolving mediator (SPM). PUFAs and Oxylipins: alpha-linolenic acid (ALA), arachidonic acid (ARA), cyclooxygenase (COX), cytochrome P450 mixed function oxidase (CYP), docosahexaenoic acid (DHA), dihydroxyeicosatrienoic acid (DHET), dihomo-gamma-linolenic acid (DHGLA), epoxyeicosatrienoic acid (EET), eicosapentaenoic acid (EPA), eicosatetraenoic acid (ETE), gamma-linolenic acid (GLA), hydroxyeicosatetraenoic acid (HETE), hydroxyheptadecatrienoic (HHT), hydroxyoctadecadienoic acid (HODE), linoleic acid (LA), lipoxygenase (LOX), leukotriene (LT), lipoxin (LX), prostaglandin (PG), phospholipase A (PLA), soluble epoxide hydrolase (sEH), and thromboxane (Tx).</p></glossary><ref-list><title>References</title><ref id="B1-ijms-25-13530"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huber-Lang</surname><given-names>M.</given-names></name>
<name><surname>Lambris</surname><given-names>J.D.</given-names></name>
<name><surname>Ward</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Innate immune responses to trauma</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>327</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0064-8</pub-id><pub-id pub-id-type="pmid">29507356</pub-id>
</element-citation></ref><ref id="B2-ijms-25-13530"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Norris</surname><given-names>P.C.</given-names></name>
<name><surname>Gosselin</surname><given-names>D.</given-names></name>
<name><surname>Reichart</surname><given-names>D.</given-names></name>
<name><surname>Glass</surname><given-names>C.K.</given-names></name>
<name><surname>Dennis</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Phospholipase A2 regulates eicosanoid class switching during inflammasome activation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>12746</fpage><lpage>12751</lpage><pub-id pub-id-type="doi">10.1073/pnas.1404372111</pub-id><pub-id pub-id-type="pmid">25139986</pub-id>
</element-citation></ref><ref id="B3-ijms-25-13530"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dyall</surname><given-names>S.C.</given-names></name>
<name><surname>Balas</surname><given-names>L.</given-names></name>
<name><surname>Bazan</surname><given-names>N.G.</given-names></name>
<name><surname>Brenna</surname><given-names>J.T.</given-names></name>
<name><surname>Chiang</surname><given-names>N.</given-names></name>
<name><surname>Da Costa Souza</surname><given-names>F.</given-names></name>
<name><surname>Dalli</surname><given-names>J.</given-names></name>
<name><surname>Durand</surname><given-names>T.</given-names></name>
<name><surname>Galano</surname><given-names>J.-M.</given-names></name>
<name><surname>Lein</surname><given-names>P.J.</given-names></name>
<etal/>
</person-group><article-title>Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions</article-title><source>Prog. Lipid Res.</source><year>2022</year><volume>86</volume><fpage>101165</fpage><pub-id pub-id-type="doi">10.1016/j.plipres.2022.101165</pub-id><pub-id pub-id-type="pmid">35508275</pub-id>
</element-citation></ref><ref id="B4-ijms-25-13530"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dennis</surname><given-names>E.A.</given-names></name>
<name><surname>Norris</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Eicosanoid storm in infection and inflammation</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>511</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/nri3859</pub-id><pub-id pub-id-type="pmid">26139350</pub-id>
</element-citation></ref><ref id="B5-ijms-25-13530"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brennan</surname><given-names>E.</given-names></name>
<name><surname>Kantharidis</surname><given-names>P.</given-names></name>
<name><surname>Cooper</surname><given-names>M.E.</given-names></name>
<name><surname>Godson</surname><given-names>C.</given-names></name>
</person-group><article-title>Pro-resolving lipid mediators: Regulators of inflammation, metabolism and kidney function</article-title><source>Nat. Rev. Nephrol.</source><year>2021</year><volume>17</volume><fpage>725</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/s41581-021-00454-y</pub-id><pub-id pub-id-type="pmid">34282342</pub-id>
</element-citation></ref><ref id="B6-ijms-25-13530"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehrotra</surname><given-names>P.</given-names></name>
<name><surname>Maschalidi</surname><given-names>S.</given-names></name>
<name><surname>Boeckaerts</surname><given-names>L.</given-names></name>
<name><surname>Mauer&#x000f6;der</surname><given-names>C.</given-names></name>
<name><surname>Tixeira</surname><given-names>R.</given-names></name>
<name><surname>Pinney</surname><given-names>J.</given-names></name>
<name><surname>Burgoa Card&#x000e1;s</surname><given-names>J.</given-names></name>
<name><surname>Sukhov</surname><given-names>V.</given-names></name>
<name><surname>Incik</surname><given-names>Y.</given-names></name>
<name><surname>Anderson</surname><given-names>C.J.</given-names></name>
<etal/>
</person-group><article-title>Oxylipins and metabolites from pyroptotic cells act as promoters of tissue repair</article-title><source>Nature</source><year>2024</year><volume>631</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07585-9</pub-id><pub-id pub-id-type="pmid">38926576</pub-id>
</element-citation></ref><ref id="B7-ijms-25-13530"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dorow</surname><given-names>J.</given-names></name>
<name><surname>Becker</surname><given-names>S.</given-names></name>
<name><surname>Kortz</surname><given-names>L.</given-names></name>
<name><surname>Thiery</surname><given-names>J.</given-names></name>
<name><surname>Hauschildt</surname><given-names>S.</given-names></name>
<name><surname>Ceglarek</surname><given-names>U.</given-names></name>
</person-group><article-title>Preanalytical investigation of polyunsaturated fatty acids and eicosanoids in human plasma by liquid chromatography-tandem mass spectrometry</article-title><source>Biopreserv. Biobank.</source><year>2016</year><volume>14</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1089/bio.2015.0005</pub-id><pub-id pub-id-type="pmid">26886177</pub-id>
</element-citation></ref><ref id="B8-ijms-25-13530"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kortz</surname><given-names>L.</given-names></name>
<name><surname>Dorow</surname><given-names>J.</given-names></name>
<name><surname>Becker</surname><given-names>S.</given-names></name>
<name><surname>Thiery</surname><given-names>J.</given-names></name>
<name><surname>Ceglarek</surname><given-names>U.</given-names></name>
</person-group><article-title>Fast liquid chromatography-quadrupole linear ion trap-mass spectrometry analysis of polyunsaturated fatty acids and eicosanoids in human plasma</article-title><source>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</source><year>2013</year><volume>927</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.jchromb.2013.03.012</pub-id></element-citation></ref><ref id="B9-ijms-25-13530"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heiling</surname><given-names>S.</given-names></name>
<name><surname>Knutti</surname><given-names>N.</given-names></name>
<name><surname>Scherr</surname><given-names>F.</given-names></name>
<name><surname>Geiger</surname><given-names>J.</given-names></name>
<name><surname>Weikert</surname><given-names>J.</given-names></name>
<name><surname>Rose</surname><given-names>M.</given-names></name>
<name><surname>Jahns</surname><given-names>R.</given-names></name>
<name><surname>Ceglarek</surname><given-names>U.</given-names></name>
<name><surname>Scherag</surname><given-names>A.</given-names></name>
<name><surname>Kiehntopf</surname><given-names>M.</given-names></name>
</person-group><article-title>Metabolite ratios as quality indicators for pre-analytical variation in serum and EDTA plasma</article-title><source>Metabolites</source><year>2021</year><volume>11</volume><elocation-id>638</elocation-id><pub-id pub-id-type="doi">10.3390/metabo11090638</pub-id><pub-id pub-id-type="pmid">34564454</pub-id>
</element-citation></ref><ref id="B10-ijms-25-13530"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>VanDerHeyden</surname><given-names>N.</given-names></name>
<name><surname>Cox</surname><given-names>T.B.</given-names></name>
</person-group><article-title>Trauma scoring</article-title><source>Current Therapy of Trauma and Surgical Critical Care</source><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2015</year></element-citation></ref><ref id="B11-ijms-25-13530"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Namas</surname><given-names>R.A.</given-names></name>
<name><surname>Vodovotz</surname><given-names>Y.</given-names></name>
<name><surname>Peitzman</surname><given-names>A.B.</given-names></name>
<name><surname>Simmons</surname><given-names>R.L.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Mi</surname><given-names>Q.</given-names></name>
<name><surname>Billiar</surname><given-names>T.R.</given-names></name>
</person-group><article-title>Unsupervised clustering analysis based on MODS severity identifies four distinct organ dysfunction patterns in severely injured blunt trauma patients</article-title><source>Front. Med.</source><year>2020</year><volume>7</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2020.00046</pub-id></element-citation></ref><ref id="B12-ijms-25-13530"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamaguchi</surname><given-names>M.</given-names></name>
<name><surname>Wu</surname><given-names>H.N.</given-names></name>
<name><surname>Tanaka</surname><given-names>M.</given-names></name>
<name><surname>Tsuda</surname><given-names>N.</given-names></name>
<name><surname>Tantengco</surname><given-names>O.A.G.</given-names></name>
<name><surname>Matsushima</surname><given-names>T.</given-names></name>
<name><surname>Nakao</surname><given-names>T.</given-names></name>
<name><surname>Ishibe</surname><given-names>T.</given-names></name>
<name><surname>Sakata</surname><given-names>I.</given-names></name>
<name><surname>Yanagihara</surname><given-names>I.</given-names></name>
</person-group><article-title>A case series of the dynamics of lipid mediators in patients with sepsis</article-title><source>Acute Med. Surg.</source><year>2019</year><volume>6</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1002/ams2.443</pub-id><pub-id pub-id-type="pmid">31592324</pub-id>
</element-citation></ref><ref id="B13-ijms-25-13530"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harris</surname><given-names>W.S.</given-names></name>
<name><surname>Tintle</surname><given-names>N.L.</given-names></name>
<name><surname>Imamura</surname><given-names>F.</given-names></name>
<name><surname>Qian</surname><given-names>F.</given-names></name>
<name><surname>Korat</surname><given-names>A.V.A.</given-names></name>
<name><surname>Marklund</surname><given-names>M.</given-names></name>
<name><surname>Djouss&#x000e9;</surname><given-names>L.</given-names></name>
<name><surname>Bassett</surname><given-names>J.K.</given-names></name>
<name><surname>Carmichael</surname><given-names>P.-H.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-Y.</given-names></name>
<etal/>
</person-group><article-title>Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>2329</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22370-2</pub-id><pub-id pub-id-type="pmid">33888689</pub-id>
</element-citation></ref><ref id="B14-ijms-25-13530"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strassburg</surname><given-names>K.</given-names></name>
<name><surname>Huijbrechts</surname><given-names>A.M.L.</given-names></name>
<name><surname>Kortekaas</surname><given-names>K.A.</given-names></name>
<name><surname>Lindeman</surname><given-names>J.H.</given-names></name>
<name><surname>Pedersen</surname><given-names>T.L.</given-names></name>
<name><surname>Dane</surname><given-names>A.</given-names></name>
<name><surname>Berger</surname><given-names>R.</given-names></name>
<name><surname>Brenkman</surname><given-names>A.</given-names></name>
<name><surname>Hankemeier</surname><given-names>T.</given-names></name>
<name><surname>van Duynhoven</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: Application in cardiac surgery</article-title><source>Ana Bioanal. Chem.</source><year>2012</year><volume>404</volume><fpage>1413</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1007/s00216-012-6226-x</pub-id><pub-id pub-id-type="pmid">22814969</pub-id>
</element-citation></ref><ref id="B15-ijms-25-13530"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vangaveti</surname><given-names>V.</given-names></name>
<name><surname>Baune</surname><given-names>B.T.</given-names></name>
<name><surname>Kennedy</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Hydroxyoctadecadienoic acids: Novel regulators of macrophage differentiation and atherogenesis</article-title><source>Ther. Adv. Endocrinol. Metab.</source><year>2010</year><volume>1</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1177/2042018810375656</pub-id><pub-id pub-id-type="pmid">23148150</pub-id>
</element-citation></ref><ref id="B16-ijms-25-13530"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morisseau</surname><given-names>C.</given-names></name>
<name><surname>Hammock</surname><given-names>B.D.</given-names></name>
</person-group><article-title>Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2013</year><volume>53</volume><fpage>37</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011112-140244</pub-id><pub-id pub-id-type="pmid">23020295</pub-id>
</element-citation></ref><ref id="B17-ijms-25-13530"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spector</surname><given-names>A.A.</given-names></name>
<name><surname>Norris</surname><given-names>A.W.</given-names></name>
</person-group><article-title>Action of epoxyeicosatrienoic acids on cellular function</article-title><source>Am. J. Physiol. Cell Physiol.</source><year>2007</year><volume>292</volume><fpage>C996</fpage><lpage>C1012</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00402.2006</pub-id><pub-id pub-id-type="pmid">16987999</pub-id>
</element-citation></ref><ref id="B18-ijms-25-13530"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomson</surname><given-names>S.J.</given-names></name>
<name><surname>Askari</surname><given-names>A.</given-names></name>
<name><surname>Bishop-Bailey</surname><given-names>D.</given-names></name>
</person-group><article-title>Anti-inflammatory effects of epoxyeicosatrienoic acids</article-title><source>Int. J. Vasc. Med.</source><year>2012</year><volume>2012</volume><fpage>605101</fpage><pub-id pub-id-type="doi">10.1155/2012/605101</pub-id><pub-id pub-id-type="pmid">22848834</pub-id>
</element-citation></ref><ref id="B19-ijms-25-13530"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tacconelli</surname><given-names>S.</given-names></name>
<name><surname>Patrignani</surname><given-names>P.</given-names></name>
</person-group><article-title>Inside epoxyeicosatrienoic acids and cardiovascular disease</article-title><source>Front. Pharmacol.</source><year>2014</year><volume>5</volume><elocation-id>239</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2014.00239</pub-id><pub-id pub-id-type="pmid">25426071</pub-id>
</element-citation></ref><ref id="B20-ijms-25-13530"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sommer</surname><given-names>K.</given-names></name>
<name><surname>Jakob</surname><given-names>H.</given-names></name>
<name><surname>Lettenmeier</surname><given-names>T.</given-names></name>
<name><surname>Henrich</surname><given-names>D.</given-names></name>
<name><surname>Sterz</surname><given-names>J.</given-names></name>
<name><surname>Marzi</surname><given-names>I.</given-names></name>
<name><surname>Frank</surname><given-names>J.</given-names></name>
</person-group><article-title>Various effects of 11,12 EET rescue wound healing in a combined model of diabetes and ischemia</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>6519</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-33400-y</pub-id><pub-id pub-id-type="pmid">37085527</pub-id>
</element-citation></ref><ref id="B21-ijms-25-13530"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergmann</surname><given-names>C.B.</given-names></name>
<name><surname>Hammock</surname><given-names>B.D.</given-names></name>
<name><surname>Wan</surname><given-names>D.</given-names></name>
<name><surname>Gogolla</surname><given-names>F.</given-names></name>
<name><surname>Goetzman</surname><given-names>H.</given-names></name>
<name><surname>Caldwell</surname><given-names>C.C.</given-names></name>
<name><surname>Supp</surname><given-names>D.M.</given-names></name>
</person-group><article-title>TPPU treatment of burned mice dampens inflammation and generation of bioactive DHET which impairs neutrophil function</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>16555</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-96014-2</pub-id><pub-id pub-id-type="pmid">34400718</pub-id>
</element-citation></ref><ref id="B22-ijms-25-13530"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dai</surname><given-names>Y.</given-names></name>
<name><surname>Dong</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>M.</given-names></name>
<name><surname>Xiong</surname><given-names>W.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Hammock</surname><given-names>B.D.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
</person-group><article-title>Enhancement of the liver's neuroprotective role ameliorates traumatic brain injury pathology</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2023</year><volume>120</volume><fpage>e2301360120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2301360120</pub-id><pub-id pub-id-type="pmid">37339206</pub-id>
</element-citation></ref><ref id="B23-ijms-25-13530"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imig</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics</article-title><source>Pharmacol. Ther.</source><year>2018</year><volume>192</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.06.015</pub-id><pub-id pub-id-type="pmid">29964123</pub-id>
</element-citation></ref><ref id="B24-ijms-25-13530"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Endo</surname><given-names>S.</given-names></name>
<name><surname>Suganami</surname><given-names>A.</given-names></name>
<name><surname>Fukushima</surname><given-names>K.</given-names></name>
<name><surname>Senoo</surname><given-names>K.</given-names></name>
<name><surname>Araki</surname><given-names>Y.</given-names></name>
<name><surname>Regan</surname><given-names>J.W.</given-names></name>
<name><surname>Mashimo</surname><given-names>M.</given-names></name>
<name><surname>Tamura</surname><given-names>Y.</given-names></name>
<name><surname>Fujino</surname><given-names>H.</given-names></name>
</person-group><article-title>15-Keto-PGE(2) acts as a biased/partial agonist to terminate PGE(2)-evoked signaling</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>13338</fpage><lpage>13352</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013988</pub-id><pub-id pub-id-type="pmid">32727851</pub-id>
</element-citation></ref><ref id="B25-ijms-25-13530"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kourpa</surname><given-names>A.</given-names></name>
<name><surname>Kaiser-Graf</surname><given-names>D.</given-names></name>
<name><surname>Sporbert</surname><given-names>A.</given-names></name>
<name><surname>Philippe</surname><given-names>A.</given-names></name>
<name><surname>Catar</surname><given-names>R.</given-names></name>
<name><surname>Rothe</surname><given-names>M.</given-names></name>
<name><surname>Mangelsen</surname><given-names>E.</given-names></name>
<name><surname>Schulz</surname><given-names>A.</given-names></name>
<name><surname>Bolbrinker</surname><given-names>J.</given-names></name>
<name><surname>Kreutz</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>15-keto-Prostaglandin E(2) exhibits bioactive role by modulating glomerular cytoarchitecture through EP2/EP4 receptors</article-title><source>Life Sci.</source><year>2022</year><volume>310</volume><fpage>121114</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2022.121114</pub-id><pub-id pub-id-type="pmid">36273629</pub-id>
</element-citation></ref><ref id="B26-ijms-25-13530"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mitsuhashi</surname><given-names>T.</given-names></name>
<name><surname>Ikata</surname><given-names>T.</given-names></name>
<name><surname>Morimoto</surname><given-names>K.</given-names></name>
<name><surname>Tonai</surname><given-names>T.</given-names></name>
<name><surname>Katoh</surname><given-names>S.</given-names></name>
</person-group><article-title>Increased production of eicosanoids, TXA2, PGI2 and LTC4 in experimental spinal cord injuries</article-title><source>Paraplegia</source><year>1994</year><volume>32</volume><fpage>524</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/sc.1994.84</pub-id><pub-id pub-id-type="pmid">7970857</pub-id>
</element-citation></ref><ref id="B27-ijms-25-13530"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Resnick</surname><given-names>D.K.</given-names></name>
<name><surname>Nguyen</surname><given-names>P.</given-names></name>
<name><surname>Cechvala</surname><given-names>C.F.</given-names></name>
</person-group><article-title>Regional and temporal changes in prostaglandin E2 and thromboxane B2 concentrations after spinal cord injury</article-title><source>Spine J.</source><year>2001</year><volume>1</volume><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/S1529-9430(01)00130-9</pub-id><pub-id pub-id-type="pmid">14588301</pub-id>
</element-citation></ref><ref id="B28-ijms-25-13530"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aibiki</surname><given-names>M.</given-names></name>
<name><surname>Maekawa</surname><given-names>S.</given-names></name>
<name><surname>Yokono</surname><given-names>S.</given-names></name>
</person-group><article-title>Moderate hypothermia improves imbalances of thromboxane A2 and prostaglandin I2 production after traumatic brain injury in humans</article-title><source>Crit. Care Med.</source><year>2000</year><volume>28</volume><fpage>3902</fpage><lpage>3906</lpage><pub-id pub-id-type="doi">10.1097/00003246-200012000-00029</pub-id><pub-id pub-id-type="pmid">11153633</pub-id>
</element-citation></ref><ref id="B29-ijms-25-13530"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vassar</surname><given-names>M.J.</given-names></name>
<name><surname>Weber</surname><given-names>C.J.</given-names></name>
<name><surname>Holcroft</surname><given-names>J.W.</given-names></name>
</person-group><article-title>Measurement of 6-keto-PGF1 alpha and thromboxane B2 levels in critically ill surgical patients</article-title><source>Prostaglandins Leukot. Essent. Fatty Acids</source><year>1988</year><volume>33</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/0952-3278(88)90152-4</pub-id><pub-id pub-id-type="pmid">3174719</pub-id>
</element-citation></ref><ref id="B30-ijms-25-13530"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schuchardt</surname><given-names>J.P.</given-names></name>
<name><surname>Ostermann</surname><given-names>A.I.</given-names></name>
<name><surname>Stork</surname><given-names>L.</given-names></name>
<name><surname>Fritzsch</surname><given-names>S.</given-names></name>
<name><surname>Kohrs</surname><given-names>H.</given-names></name>
<name><surname>Greupner</surname><given-names>T.</given-names></name>
<name><surname>Hahn</surname><given-names>A.</given-names></name>
<name><surname>Schebb</surname><given-names>N.H.</given-names></name>
</person-group><article-title>Effect of DHA supplementation on oxylipin levels in plasma and immune cell stimulated blood</article-title><source>Prostaglandins Leukot. Essent. Fatty Acids</source><year>2017</year><volume>121</volume><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.plefa.2017.06.007</pub-id><pub-id pub-id-type="pmid">28651702</pub-id>
</element-citation></ref><ref id="B31-ijms-25-13530"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Janssen</surname><given-names>C.I.F.</given-names></name>
<name><surname>Kiliaan</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration</article-title><source>Prog. Lipid Res.</source><year>2014</year><volume>53</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.plipres.2013.10.002</pub-id><pub-id pub-id-type="pmid">24334113</pub-id>
</element-citation></ref><ref id="B32-ijms-25-13530"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anthonymuthu</surname><given-names>T.S.</given-names></name>
<name><surname>Kenny</surname><given-names>E.M.</given-names></name>
<name><surname>Amoscato</surname><given-names>A.A.</given-names></name>
<name><surname>Lewis</surname><given-names>J.</given-names></name>
<name><surname>Kochanek</surname><given-names>P.M.</given-names></name>
<name><surname>Kagan</surname><given-names>V.E.</given-names></name>
<name><surname>Bay&#x00131;r</surname><given-names>H.</given-names></name>
</person-group><article-title>Global assessment of oxidized free fatty acids in brain reveals an enzymatic predominance to oxidative signaling after trauma</article-title><source>Biochim. Biophys. Acta</source><year>2017</year><volume>1863</volume><fpage>2601</fpage><lpage>2613</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2017.03.015</pub-id><pub-id pub-id-type="pmid">28347845</pub-id>
</element-citation></ref><ref id="B33-ijms-25-13530"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallah</surname><given-names>K.</given-names></name>
<name><surname>Quanico</surname><given-names>J.</given-names></name>
<name><surname>Trede</surname><given-names>D.</given-names></name>
<name><surname>Kobeissy</surname><given-names>F.</given-names></name>
<name><surname>Zibara</surname><given-names>K.</given-names></name>
<name><surname>Salzet</surname><given-names>M.</given-names></name>
<name><surname>Fournier</surname><given-names>I.</given-names></name>
</person-group><article-title>Lipid changes associated with traumatic brain injury revealed by 3D MALDI-MSI</article-title><source>Anal. Chem.</source><year>2018</year><volume>90</volume><fpage>10568</fpage><lpage>10576</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.8b02682</pub-id><pub-id pub-id-type="pmid">30070841</pub-id>
</element-citation></ref><ref id="B34-ijms-25-13530"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farias</surname><given-names>S.E.</given-names></name>
<name><surname>Heidenreich</surname><given-names>K.A.</given-names></name>
<name><surname>Wohlauer</surname><given-names>M.V.</given-names></name>
<name><surname>Murphy</surname><given-names>R.C.</given-names></name>
<name><surname>Moore</surname><given-names>E.E.</given-names></name>
</person-group><article-title>Lipid mediators in cerebral spinal fluid of traumatic brain injured patients</article-title><source>J. Trauma.</source><year>2011</year><volume>71</volume><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1097/TA.0b013e3182092c62</pub-id><pub-id pub-id-type="pmid">21427623</pub-id>
</element-citation></ref><ref id="B35-ijms-25-13530"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Orr</surname><given-names>S.K.</given-names></name>
<name><surname>Butler</surname><given-names>K.L.</given-names></name>
<name><surname>Hayden</surname><given-names>D.</given-names></name>
<name><surname>Tompkins</surname><given-names>R.G.</given-names></name>
<name><surname>Serhan</surname><given-names>C.N.</given-names></name>
<name><surname>Irimia</surname><given-names>D.</given-names></name>
</person-group><article-title>Gene expression of proresolving lipid mediator pathways is associated with clinical outcomes in trauma patients</article-title><source>Crit. Care Med.</source><year>2015</year><volume>43</volume><fpage>2642</fpage><lpage>2650</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000001312</pub-id><pub-id pub-id-type="pmid">26488221</pub-id>
</element-citation></ref><ref id="B36-ijms-25-13530"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Basil</surname><given-names>M.C.</given-names></name>
<name><surname>Levy</surname><given-names>B.D.</given-names></name>
</person-group><article-title>Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>51</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/nri.2015.4</pub-id><pub-id pub-id-type="pmid">26688348</pub-id>
</element-citation></ref><ref id="B37-ijms-25-13530"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chiang</surname><given-names>N.</given-names></name>
<name><surname>Serhan</surname><given-names>C.N.</given-names></name>
</person-group><article-title>Specialized pro-resolving mediator network: An update on production and actions</article-title><source>Essays Biochem.</source><year>2020</year><volume>64</volume><fpage>443</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1042/EBC20200018</pub-id><pub-id pub-id-type="pmid">32885825</pub-id>
</element-citation></ref><ref id="B38-ijms-25-13530"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schebb</surname><given-names>N.H.</given-names></name>
<name><surname>K&#x000fc;hn</surname><given-names>H.</given-names></name>
<name><surname>Kahnt</surname><given-names>A.S.</given-names></name>
<name><surname>Rund</surname><given-names>K.M.</given-names></name>
<name><surname>O'Donnell</surname><given-names>V.B.</given-names></name>
<name><surname>Flamand</surname><given-names>N.</given-names></name>
<name><surname>Peters-Golden</surname><given-names>M.</given-names></name>
<name><surname>Jakobsson</surname><given-names>P.-J.</given-names></name>
<name><surname>Weylandt</surname><given-names>K.H.</given-names></name>
<name><surname>Rohwer</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Formation, signaling and occurrence of specialized pro-resolving lipid mediators-What is the evidence so far?</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><elocation-id>838782</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2022.838782</pub-id><pub-id pub-id-type="pmid">35308198</pub-id>
</element-citation></ref><ref id="B39-ijms-25-13530"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calder</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake</article-title><source>Biochimie</source><year>2020</year><volume>178</volume><fpage>105</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2020.08.015</pub-id><pub-id pub-id-type="pmid">32860894</pub-id>
</element-citation></ref><ref id="B40-ijms-25-13530"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O'Donnell</surname><given-names>V.B.</given-names></name>
<name><surname>Schebb</surname><given-names>N.H.</given-names></name>
<name><surname>Milne</surname><given-names>G.L.</given-names></name>
<name><surname>Murphy</surname><given-names>M.P.</given-names></name>
<name><surname>Thomas</surname><given-names>C.P.</given-names></name>
<name><surname>Steinhilber</surname><given-names>D.</given-names></name>
<name><surname>Gelhaus</surname><given-names>S.L.</given-names></name>
<name><surname>K&#x000fc;hn</surname><given-names>H.</given-names></name>
<name><surname>Gelb</surname><given-names>M.H.</given-names></name>
<name><surname>Jakobsson</surname><given-names>P.-J.</given-names></name>
<etal/>
</person-group><article-title>Failure to apply standard limit-of-detection or limit-of-quantitation criteria to specialized pro-resolving mediator analysis incorrectly characterizes their presence in biological samples</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>7172</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41766-w</pub-id><pub-id pub-id-type="pmid">37945602</pub-id>
</element-citation></ref><ref id="B41-ijms-25-13530"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chaves-Filho</surname><given-names>A.B.</given-names></name>
<name><surname>Diniz</surname><given-names>L.S.</given-names></name>
<name><surname>Santos</surname><given-names>R.S.</given-names></name>
<name><surname>Lima</surname><given-names>R.S.</given-names></name>
<name><surname>Oreliana</surname><given-names>H.</given-names></name>
<name><surname>Pinto</surname><given-names>I.F.D.</given-names></name>
<name><surname>Dantas</surname><given-names>L.S.</given-names></name>
<name><surname>Inague</surname><given-names>A.</given-names></name>
<name><surname>Faria</surname><given-names>R.L.</given-names></name>
<name><surname>Medeiros</surname><given-names>M.H.G.</given-names></name>
<etal/>
</person-group><article-title>Plasma oxylipin profiling by high resolution mass spectrometry reveal signatures of inflammation and hypermetabolism in amyotrophic lateral sclerosis</article-title><source>Free Radic. Biol. Med.</source><year>2023</year><volume>208</volume><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2023.08.019</pub-id><pub-id pub-id-type="pmid">37619957</pub-id>
</element-citation></ref><ref id="B42-ijms-25-13530"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pauls</surname><given-names>S.D.</given-names></name>
<name><surname>Du</surname><given-names>Y.</given-names></name>
<name><surname>Clair</surname><given-names>L.</given-names></name>
<name><surname>Winter</surname><given-names>T.</given-names></name>
<name><surname>Aukema</surname><given-names>H.M.</given-names></name>
<name><surname>Taylor</surname><given-names>C.G.</given-names></name>
<name><surname>Zahradka</surname><given-names>P.</given-names></name>
</person-group><article-title>Impact of age, menopause, and obesity on oxylipins linked to vascular health</article-title><source>Arterioscler.Thromb.Vasc.Biol.</source><year>2021</year><volume>41</volume><fpage>883</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.315133</pub-id><pub-id pub-id-type="pmid">33380172</pub-id>
</element-citation></ref><ref id="B43-ijms-25-13530"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Beutner</surname><given-names>F.</given-names></name>
<name><surname>Teupser</surname><given-names>D.</given-names></name>
<name><surname>Gielen</surname><given-names>S.</given-names></name>
<name><surname>Holdt</surname><given-names>L.M.</given-names></name>
<name><surname>Scholz</surname><given-names>M.</given-names></name>
<name><surname>Boudriot</surname><given-names>E.</given-names></name>
<name><surname>Schuler</surname><given-names>G.</given-names></name>
<name><surname>Thiery</surname><given-names>J.</given-names></name>
</person-group><article-title>Rationale and design of the Leipzig (LIFE) Heart Study: Phenotyping and cardiovascular characteristics of patients with coronary artery disease</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e29070</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029070</pub-id><pub-id pub-id-type="pmid">22216169</pub-id>
</element-citation></ref><ref id="B44-ijms-25-13530"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weissgerber</surname><given-names>A.</given-names></name>
<name><surname>Scholz</surname><given-names>M.</given-names></name>
<name><surname>Teren</surname><given-names>A.</given-names></name>
<name><surname>Sandri</surname><given-names>M.</given-names></name>
<name><surname>Teupser</surname><given-names>D.</given-names></name>
<name><surname>Gielen</surname><given-names>S.</given-names></name>
<name><surname>Thiery</surname><given-names>J.</given-names></name>
<name><surname>Schuler</surname><given-names>G.</given-names></name>
<name><surname>Beutner</surname><given-names>F.</given-names></name>
</person-group><article-title>The value of noncoronary atherosclerosis for identifying coronary artery disease: Results of the Leipzig LIFE Heart Study</article-title><source>Clin. Res. Cardiol.</source><year>2016</year><volume>105</volume><fpage>172</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1007/s00392-015-0900-x</pub-id><pub-id pub-id-type="pmid">26362881</pub-id>
</element-citation></ref><ref id="B45-ijms-25-13530"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>K.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Shao</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>P.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Du</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Therapeutic and prognostic significance of arachidonic acid in heart failure</article-title><source>Circ. Res.</source><year>2022</year><volume>130</volume><fpage>1056</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.320548</pub-id><pub-id pub-id-type="pmid">35255710</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-25-13530-f001"><label>Figure 1</label><caption><p>Post-traumatic time course of circulating PUFAs. (<bold>A</bold>) Comparison of the PUFA levels between controls and all patients (one-way ANOVA). (<bold>B</bold>) Comparison of the PUFA levels between patient groups (mixed effect model). (<bold>C</bold>) Ratio of the concentration of &#x003c9;6 PUFA/&#x003c9; PUFA in controls and all patients (one-way ANOVA). * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="ijms-25-13530-g001" position="float"/></fig><fig position="float" id="ijms-25-13530-f002"><label>Figure 2</label><caption><p>PUFA-derived oxylipins detectable in injured patients PUFAs are encircled. The metabolites are arranged mainly according to the pathway in which they are generated (cyclooxygenases, COX; lipoxygenases, LOX; cytochrome P450 mixed function oxidase enzymes, CYP; nonenzymatic free-radical mechanisms, non). Metabolites in black: present in almost all patients, metabolites in blue: present in some patients; metabolites in grey: not detected at any time point in patients. *, **, *** these PUFAs/metabolites were quantified together.</p></caption><graphic xlink:href="ijms-25-13530-g002" position="float"/></fig><fig position="float" id="ijms-25-13530-f003"><label>Figure 3</label><caption><p>Comparison of the frequencies of controls and patients for those oxylipins that were detected in some (less than 90%) of the patients at any time point. At each time point after trauma the frequency (%) of controls (ctr), all patients, and of the 3 patient groups are indicated. * Only significant differences between controls and all patients at 1 h after injury are noted (Fisher&#x02019;s exact test, <italic toggle="yes">p</italic>-value). Oxylipins present at each time point in almost all patients are not included in this figure.</p></caption><graphic xlink:href="ijms-25-13530-g003" position="float"/></fig><fig position="float" id="ijms-25-13530-f004"><label>Figure 4</label><caption><p>Post-traumatic time course of circulating LA-derived 9- and 13-HODE (<bold>A</bold>) and ARA-derived DHETs (<bold>B</bold>). Comparison between controls and all patients: one-way ANOVA; comparison between the indicated patient groups: mixed effect model; * <italic toggle="yes">p</italic> &#x0003c; 0.05, ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001, **** <italic toggle="yes">p</italic> &#x0003c; 0.0001.</p></caption><graphic xlink:href="ijms-25-13530-g004" position="float"/></fig><fig position="float" id="ijms-25-13530-f005"><label>Figure 5</label><caption><p>Correlation of patient&#x02019;s clinical parameters with PUFA and oxylipin levels 1 to 240 h after trauma. In the correlation matrix, the square color indicates the magnitude of correlation (Spearman). Only oxylipins with significant correlations are shown. Oxylipins with less than 50% of the patients with detected values at the indicated time point were not analyzed (grey lines in the respective fields). In this analysis, values not detected in a present sample were not imputed.</p></caption><graphic xlink:href="ijms-25-13530-g005" position="float"/></fig><table-wrap position="float" id="ijms-25-13530-t001"><object-id pub-id-type="pii">ijms-25-13530-t001_Table 1</object-id><label>Table 1</label><caption><p>Patients&#x02019; characteristics grouped according to the ISS.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Traumatized Patients</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1"><italic toggle="yes">p</italic> Value *</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group 1,<break/>ISS &#x0003c; 16</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group 2,<break/>ISS 16&#x02013;24</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group 3,<break/>ISS &#x02265; 25</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Comparing Group</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">patients (n)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ISS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5 (9.0&#x02013;13.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.0 (19.0&#x02013;21.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41.0 (34.0&#x02013;50.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">age (years)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.5 (32.0&#x02013;68.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.0 (35.0&#x02013;70.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53.0 (34.0&#x02013;59.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.849</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.599</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.455</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">sex, female (n)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.126</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">days at ICU (n)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 (2.0&#x02013;3.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0 (2.0&#x02013;8.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.0 (6.0&#x02013;34.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">days in hospital (n)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.0 (7.0&#x02013;16.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.0 (12.0&#x02013;17.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.0 (16.0&#x02013;42.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.732</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.217</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.007</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">death in hospital (n)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SOFA score at 24 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0 (1.0&#x02013;3.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.0 (1.0&#x02013;4.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.0 (5.0&#x02013;9.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.880</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.087</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr></tbody></table><table-wrap-foot><fn><p>Values are given as median with interquartile range. * Kruskal&#x02013;Wallis H test; Sequential Organ Failure Assessment (SOFA).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-25-13530-t002"><object-id pub-id-type="pii">ijms-25-13530-t002_Table 2</object-id><label>Table 2</label><caption><p>Targeted PUFAs and PUFA-derived oxylipins were detected in injured patients and controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PUFA/Metabolite</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Present in Controls (n = 25)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PUFA/Metabolite Derived From</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">1st; 2nd Pathway</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Fatty Acid</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Molecular Formula</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C18H32O2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLA/ALA *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C18H30O2 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DHGLA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H30O2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DHA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C22H32O2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9-HODE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX; peroxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C18H32O3 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13-HODE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX; peroxidation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C18H32O3 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">6-keto-PGF1a</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O6 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">TxB2</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O6 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">11-dehydro-TxB2</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O6 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">12(S)-HHT</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C17H28O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">11b-PGF2a</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O5 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">PGJ2</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">PGE2</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">11b-PGE2/15-keto-PGF2a **</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">13,14-dihydro-15-keto-PGE2</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">PGF2a</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O5 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">13,14-dihydro-15-keto-PGF2a</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COX2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O5 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5(S)-HETE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX; CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8(S)-HETE/12(S)-HETE ***</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX; CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">12-oxo-ETE</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">-</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LOX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H30O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">tetranor-12(S)-HETE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peroxidation; LOX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C16H26O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15(S)-HETE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15-LOX-1/2; CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">LTE4</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#2F5496">-</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-LOX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C23H37NO5S</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5,6-DHET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8,9-DHET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11,12-DHET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4472C4">14,15-EET</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14,15-DHET</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H34O4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16(S)-HETE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4472C4">17(S)-HETE</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4F81BD">-</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4472C4">18-HETE</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP/LOX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4472C4">19(S)-HETE</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4472C4">20-HETE</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4F81BD">-</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<named-content content-type="color:#4472C4">9(S)-HETE</named-content>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peroxidation; CYP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11(S)-HETE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">peroxidation; COX, LOX</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c9; 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C20H32O3</td></tr></tbody></table><table-wrap-foot><fn><p>PUFA and metabolites detected in almost all patients are in black, and those detected in some patients are in blue; *, **, *** these PUFAs/metabolites were quantified together.</p></fn></table-wrap-foot></table-wrap></floats-group></article>